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Background: Brain derived neurotrophic factor (BDNF) belongs to a family of structurally related proteins called
neurotrophins that have been shown to regulate survival and growth of neurons in the developing central and
peripheral nervous system and also to take part in synaptic plasticity related processes in adulthood. Since BDNF is
associated with several nervous system disorders it would be beneficial to have cellular reporter system for studying
its expression regulation.
Methods: Using modified bacterial artificial chromosome (BAC), we generated several transgenic cell lines
expressing humanised Renilla luciferase (hRluc)-EGFP fusion reporter gene under the control of rat BDNF gene
regulatory sequences (rBDNF-hRluc-EGFP) in HeLa background. To see if the hRluc-EGFP reporter was regulated in
response to known regulators of BDNF expression we treated cell lines with substances known to regulate BDNF
and also overexpressed transcription factors known to regulate BDNF gene in established cell lines.
Results: rBDNF-hRluc-EGFP cell lines had high transgene copy numbers when assayed with qPCR and FISH analysis
showed that transgene was maintained episomally in all cell lines. Luciferase activity in transgenic cell lines was
induced in response to ionomycin-mediated rise of intracellular calcium levels, treatment with HDAC inhibitors and
by over-expression of transcription factors known to increase BDNF expression, indicating that transcription of the
transgenic reporter is regulated similarly to the endogenous BDNF gene.
Conclusions: Generated rBDNF-hRluc-EGFP BAC cell lines respond to known modulators of BDNF expression and
could be used for screening of compounds/small molecules or transcription factors altering BDNF expression.
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Brain derived neurotrophic factor (BDNF), a nerve growth
factor family member [1], has been shown to have import-
ant roles in the development and functioning of nervous
system [2]. During development, BDNF supports survival
and differentiation of distinct neuronal subpopulations
[1,3,4]. In adulthood, BDNF has been shown to have ef-
fects in activity-dependent synaptic plasticity including
learning and long-term potentiation [5], pain modulation
[6], synaptogenesis [7,8] and regulation of metabolism [9].
BDNF gene has complex transcriptional regulation
with different untranslated 5′ exons spliced to a com-
mon protein coding 3′ exon. Nine different promoters
(I-IX) controlling transcription from nine or eleven 5′* Correspondence: kaur.jaanson@ttu.ee
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unless otherwise stated.exons, in rodents or humans respectively, and two differ-
ent polyadenylation sites give rise to a range of mRNAs
[10-12]. BDNF transcription has been shown to be regu-
lated by a multitude of transcription factors (reviewed in
[13]), for instance promoter I by cAMP response elem-
ent binding protein (CREB) [14], upstream stimulatory
factors (USF) [14], myocyte enhancer factor 2D (MEF2D)
[15], nuclear factor kappa beta (NFκB) [16], basic helix-
loop-helix (bHLH)-PAS transcription factor neuronal PAS
domain protein 4 (NPAS4) and aryl hydrocarbon receptor
nuclear translocator 2 (ARNT2) heterodimer (NPAS4-
ARNT2) [17,18]; promoter II by repressor element-1 tran-
scription factor (REST) [19,20]; promoter IV by CREB
[21,22], calcium response factor (CaRF) [23], USF-s
[18,24], methyl CpG binding protein 2 (MeCP2) [25],
NFκB [26], bHLHB2 [27], and NPAS4-ARNT2 hetero-
dimer [17,18], MEF2C [28]; promoter IX by CREB andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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many promoters and resulting large number of transcripts
with the same protein coding sequence but alternating 5′
and 3′ untranslated regions, BDNF expression is tempor-
ally and spatially controlled in different tissues [11,12,29],
developmental stages [30] and within different cell com-
partments [31-33]. Additionally, the BDNF gene locus also
encompasses the antisense BDNF gene (BDNFOS) [12,34,35]
with a complex splicing and expression pattern. Transcripts
of the antisense BDNF gene have been shown to form
dsRNA duplexes with BDNF transcripts [12] and regulate
BDNF levels [35] in vivo.
Alterations in BDNF expression have been associated
with several neurodegenerative disorders. BDNF expres-
sion has been shown to be decreased in brains of Alzhei-
mer’s [36], Parkinson’s [37,38] and Huntington’s disease
[39] patients. Changes of BDNF levels are accompanied
by several other pathologies, like neuropsychiatric dis-
orders, obesity, impairment of learning and memory,
neuropathic pain and epileptogenesis [2]. Due to BDNF in-
volvement in nervous system disorders, it has been of great
interest to use it as a therapeutic [40]. Unfortunately, direct
use of recombinant BDNF protein is problematic due to its
low serum half-life, poor penetration across blood brain bar-
rier and low diffusion properties in tissues. Delivery of
BDNF into the brain using viral vectors can have problems
with vector toxicity, expression dosage and insertional muta-
genesis. These problems have promoted screening of drug
candidates that could promote expression of endogenous
BDNF [41]. HDAC inhibitors are one class of drugs that
have been shown to mediate their effect on memory and
synaptic plasticity in models of nervous system disorders
through increase in BDNF expression [42,43].
Bacterial artificial chromosomes (BACs) are large cap-
acity vectors which are easy to maintain and modify
using homologous recombination in E. coli [44]. Due to
their large size, BACs can incorporate whole gene gen-
omic loci while at the same time being easier to handle
and modify than yeast artificial chromosomes (YACs).
BACs have been used to create transgenic mice and cell
lines for studying protein function [45], expression regu-
lation [46-48] and for use in high-throughput screening
of gene expression modulators [49].
Our group has previously created transgenic mice using
BACs containing human [50] or rat [51] BDNF genomic
sequences. Transgenes in these mice recapitulated en-
dogenous BDNF expression patterns in different tis-
sues. In the current study, we have generated transgenic
cell lines expressing humanised Renilla luciferase (hRluc)-
EGFP fusion reporter gene under the control of rat BDNF
gene regulatory sequences. To this end we used BAC con-
taining rat BDNF gene locus with BDNF protein coding
region replaced with the hRluc-EGFP coding sequence.
These transgenes maintain transgene episomally in highnumbers and express reporter gene at high levels. Re-
porter gene is induced in response to rise in intracellular
calcium levels, treatment with different HDAC inhibitors
and overexpression of NPAS4-ARNT2 heterodimer or
constitutively active CREB1 (VP16-CREB) that are known
to regulate BDNF expression. These transgenic cell lines
could be used for screening drug candidates or transcrip-
tion factors that modulate BDNF expression.
Results
Generation of rBDNF-hRluc-EGFP HeLa stable cell lines
HeLa cell line was chosen for generation of rBDNF-
hRluc-EGFP cell lines because its relatively carefree growth
conditions and fast growth are good properties for trans-
genic cell line. Endogenous human BDNF gene was also
expressed in HeLa cell line showing that signaling path-
ways regulating BDNF expression were active in HeLa cells
(see below). The hRluc-EGFP fusion reporter was used be-
cause EGFP fluorescence was useful for initial screening
and subcloning of transgenic cell lines by fluorescence mi-
croscopy and FACS. However for screening of substances
or transcription factors regulating BDNF expression,
Renilla luciferase luminescence detection is more sen-
sitive and gives less background signal than fluores-
cence based detection methods [52]. Renilla luciferase
also has commercial live cell substrates that allow for
repeated measurements of the treated cells making it
easier to assay the time dependent effect on the re-
porter expression while conserving reagents.
rBDNF-hRluc-EGFP BAC construct used for generat-
ing cell lines was created using BAC clone that contains
rat BDNF locus spanning 13 kb upstream of the first
exon and 144 kb downstream of the last polyadenylation
signal (Figure 1A). BAC clone was modified by homolo-
gous recombination to: (i) replace BDNF coding se-
quence with sequence coding for humanised Renilla
luciferase, Ala-Ala-Ala-Thr linker and EGFP fusion pro-
tein (Figure 1B) and (ii) replace CAT gene in BAC vector
by neo cassette to confer resistance to G418 for positive
selection during cell line generation. The final rBDNF-
hRluc-EGFP BAC construct was transfected into HeLa
cells by nucleofection and G418 was applied for selection.
Following two months of G418 selection, FACS analysis
of polyclonal cell population showed that 15% of cells were
positive for EGFP signal. Luciferase signal measured in cell
lysate was 104 times over the HeLa background signal (data
not shown). By FACS assisted cell sorting a number of sin-
gle cell clones were established displaying varying levels of
transgene expression. Six cell lines were chosen for subse-
quent analysis: 1A4s2, 1A4s3, 2A4, 2B2s, 3E2s and 3G4s.
rBDNF-hRluc-EGFP cell lines express hRluc-EGFP reporter gene
In all six cell lines, EGFP signal was detected by fluorescence




signalsATGATG13 kb 144 kb
Figure 1 Schematic drawing of the rBDNF-hRluc-EGFP-BAC construct used for generation of HeLa cell-lines expressing the transgene.
(A) The BAC used contained the rat BDNF locus spanning 13 kb upstream of the first exon and 144 kb downstream of the last polyadenylation
signal. The exonic structure of rat BDNF gene is adapted from [11]. (B) The coding region of BDNF was replaced by homologous recombination
with sequence coding for humanised Renilla luciferase, Ala-Ala-Ala-Thr linker and EGFP fusion protein. Protein coding regions are shown as gray
(BDNF), orange (hRluc) or green (EGFP) boxes. Untranslated regions are shown as white boxes.
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Flow-cytometric analysis of the six cell lines showed that
the percentage of EGFP positive cells in population varied
from 95 to 59 percent (Figure 2B). Additionally there was
a variance over several log units in reporter expression
level within a cell line (Figure 2C). This prompted us to
analyse the stability of reporter expression in time. For this
we passaged the cell lines in media containing increasing
concentrations of selective antibiotic G418 (0, 200, 400,
800 and 1200 μg/ml). If no antibiotic was added to the
growth medium then the proportion of EGFP positive
cells in different cell lines decreased 1.5 to 10 times in
three weeks. At the same time the proportion did not
change substantially when cells were grown in medium
containing 800 or 1200 μg/ml of G418 (data not shown).
Next we measured the activity of Renilla luciferase in
live cells using Enduren substrate and normalised it to
cellular ATP levels. The signals obtained from the six
cell lines were 35 to ~200 times over the background
signal of the parental HeLa cells (Figure 2D). Based on
reporter expression level we divided the cell lines into
two groups: the group with high reporter expression in-
cludes the cell lines 1A4s2, 1A4s3 and 2A4; the low
reporter expression group consists of the cell lines
2B2s, 3E2s and 3G4s. In the first group luciferase sig-
nal was ~100-200 times above background and in the sec-
ond group around ~35-60 times above background.
Having detected both, Renilla luciferase luminescence
and EGFP fluorescence, of the fusion reporter protein
we decided to determine which of the alternative chi-
maeric rat BDNF hRluc-EGFP mRNAs are transcribed
in the six cell lines. Expression of endogenous human
BDNF transcripts in the 6 cell lines were similar to par-
ental HeLa cells with a few exceptions: transcript I was
not expressed in 3G4s cell line and transcript IXa long
(corresponding to transcript IXabcd in [12]) was not
expressed in 1A4s2 cell line (Figure 3A). Using RT-PCR
analysis we were able to detect transgenic transcripts I,
III, IV, V, VI, VIII and IXa in all cell lines (Figure 3B).
Transgenic transcript I was expressed at very low levels
in five out of six cell lines, its levels were elevated in2A4 cells. Neither endogenous nor transgenic transcript
II was detected in cell lines or parental HeLa cells.
While overall expressions of endogenous and transgenic
transcripts were similar there were some differences.
First, endogenous transcript III was not expressed in any
of the cell lines while transgenic transcript III was expressed
in all cell lines. Second, transgenic transcript VII was not
expressed in any of the cell lines although being expressed
endogenously. Altogether these data show that correctly
spliced transgenic rat BDNF hRluc-EGFP mRNAs are tran-
scribed and functional hRluc-EGFP fusion protein is
expressed in rBDNF-hRluc-EGFP cell lines.
Transgene is maintained in rBDNF-hRluc-EGFP cell lines as
a high copy number episome
Since transgene integration site and copy number can
influence reporter gene expression from the transgene,
we aimed to determine the copy number and chromo-
somal state (integrated or episomal) of rBDNF-hRluc-
EGFP BAC DNA in cell lines. qPCR analysis using copy
number standard showed that transgene copy number
varied up to five times amongst the different cell lines.
Over 900 transgene copies per HeLa genome were present
in 1A4s2 and 1A4s3 cell lines and ~190-300 transgene
copies in 2A4, 2B2s, 3E2s, 3G4s cell lines (Figure 4A). The
status of transgene DNA was analysed by fluorescent in
situ hybridisation (FISH) with rBDNF-hRluc-EGFP BAC
specific probe. As demonstrated in Figure 4B, transgenic
BAC DNA was maintained episomally in all cell lines –
the rBDNF-hRluc-EGFP BAC specific hybridisation sig-
nals were localised near chromosomes, but integration
was not detected. Transgene copy numbers per cell also
varied highly between cells of the same cell line. In con-
clusion, the obtained rBDNF-hRluc-EGFP cell lines con-
tain relatively high numbers of transgenic BAC DNA per
cell that replicates episomally.
Elevated intracellular calcium induces reporter gene
expression in rBDNF-hRluc-EGFP cell lines
BDNF promoters contain several Ca2+ responsive regula-
















































Figure 2 Detection of hRluc-EGFP reporter expression in rBDNF-hRluc-EGFP cell lines. (A) Fluorescence microscopy images of rBDNF-hRluc-EGFP
cell lines. (B) Percentage of EGFP positive cells in different rBDNF-hRluc-EGFP BAC cell lines counted by fluorescence-activated cell sorting
(FACS). (C) Histograms showing the variability of reporter gene expression level within a cell population of different rBDNF-hRluc-EGFP cell
lines counted by FACS. (D) Detection of Renilla luciferase enzymatic activity in rBDNF-hRluc-EGFP cell lines relative to the background signal
measured in parental HeLa cells. Enduren luciferase live cell substrate was added with fresh culture medium to rBDNF-hRluc-EGFP cells and
HeLa cells and Renilla luciferase luminescence was measured after 12 hour incubation. Results are normalised to cell viability assayed by cellular
ATP levels after 12 hour incubation. Error bars indicate SD of three independent experiments.
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neurons [54]. To test if transgene is induced by elevated
intracellular Ca2+ levels in different cell lines we treated
cells for 12 hours with 1 μM ionomycin, a calcium iono-
phore known to induce BDNF expression in neurons
[55], and monitored Renilla luciferase signal using Endu-
ren live cell luciferase substrate during this period. Iono-
mycin treatment induced reporter gene expression in all
cell lines compared to vehicle treated control. As shown
in Figure 5A, the relative increase of luminescence signalwas higher in cell lines with low reporter expression:
3E2s, 2B2s and 3G4s. In these three cell lines the fold
change reached its peak after eight hours when it was
2.00 (p < 0.01); 1.95 (p < 0.01); and 1.86 (p < 0.05) re-
spectively. In the cell lines with high reporter expression
the fold change remained smaller and the maximum
values for cell lines 1A4s2, 1A4s3 and 2A4 were 1.46
(p < 0.05); 1.56 (p < 0.01) and 1.43 (p < 0.01) respect-
ively. To exclude the possibility that ionomycin affects

















































Figure 3 Expression of alternative 5′ exon-specific mRNAs transcribed from rBDNF-hRluc-EGFP cell lines and HeLa cells. Expression of
alternatively spliced 5′ exon specific transcripts form (A) endogenous BDNF and (B) rBDNF-hRluc-EGFP BAC reporter construct in different
rBDNF-hRluc-EGFP cell lines and parental HeLa cells. Endogenous IXa long and short transcripts correspond to human BDNF transcripts
IXabcd and IXabd in [12].
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nificant decrease in cell viability was detected in response
to ionomycin treatment (Figure 5B). These results demon-
strate that reporter expression in rBDNF-hRluc-EGFP cell
lines is regulated by changes in intracellular calcium level.
HDAC inhibitors induced reporter gene expression in
rBDNF-hRluc-EGFP cell lines
Due to interest in finding low molecular weight substances
regulating BDNF expression we sought to establish whether
our cell lines could be used for screening of substances
modulating BDNF expression. HDAC inhibitors are a class
of drugs that inhibit histone deacetylases – group of
enzymes that deacetylate histones and non-histoneA B
Figure 4 Analysis of transgene copy number and chromosomal state. (A
cell lines. Error bars show SE of three technical replicates. (B) FISH analysis of re
lines. Hybridisation was performed with rBDNF-hRluc-EGFP BAC specific probeproteins. It has been shown that certain HDAC inhibi-
tors have antidepressant actions and regulate BDNF ex-
pression [56], for example valproate [42,57-59], TSA
[58,60] and SAHA [61]. Since it would be of interest to
use our cell lines for screening of other compounds that
could epigenetically regulate BDNF expression, we tested
response of the reporter gene in BAC cell lines to four
HDAC inhibitors. Two cell lines were chosen for treat-
ments, higher copy number cell line 1A4s2 and lower
copy number cell line 3E2s. The cells were treated with
100 nM apicidin, 1 μM SAHA, 100 nM TSA and 1 mM
sodium valproate for 12 hours while assaying reporter




) qPCR analysis of transgene copy number in different rBDNF-hRluc-EGFP
porter construct chromosomal status in different rBDNF-hRluc-EGFP cell
(red signal) and DNA was stained with Hoecht 33342 (blue signal).
Figure 5 Treatment with ionomycin induces reporter expression in
different rBDNF-hRluc-EGFP cell lines. (A) Luciferase activity in 1 μM
ionomycin treated cells relative to vehicle (0.1% DMSO) treated
cells (dashed line) at each time point, measured in live cells
during 12 hours. Renilla luciferase luminescence was measured
using Enduren substrate 2–12 hours after the start of the
treatment at one hour intervals. Error bars indicate SD of three
independent experiments. (B) Cell viability in ionomycin treated
cells relative to vehicle treated cells after 12 hours in different cell
lines. Viability was assayed by cellular ATP levels. Error bars
indicate SD of three independent experiments.
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in both cell lines compared to vehicle treated control.
100 nM apicidin increased reporter gene expression in
1A4s2 and 3E2s cell lines 1.70 and 1.58 fold at 12 hours
and 11 hours of treatment, respectively (both p < 0.01,
Figure 6A). 1 μM SAHA treatment increased reporter
gene expression in 1A4s2 and 3E2s cell lines 1.65 and 1.64
fold at 12 hours and 11 hours, respectively (both p < 0.01
Figure 6B). 100 nM TSA treatment increased reporter
gene expression in 1A4s2 and 3E2s cell lines 1.63 and 1.70
fold at 12 hours and 11 hours, respectively (both p < 0.01,
Figure 6C). 1 mM sodium valproate increased reporter
gene expression in 1A4s2 and 3E2s cell lines 1.22 and 1.24
fold at 11 hours and 10 hours, respectively (p < 0.05 and
p < 0.01, Figure 6D). None of the used HDAC inhibi-
tors showed significant effect on cellular survival after12 hours of treatment in either cell line (Figure 6E and F).
Taken together, these results show that HDAC inhibitors
upregulate reporter gene expression in rBDNF-hRluc-
EGFP cell lines 1A4s2 and 3E2s.
VP16-CREB and NPAS4-ARNT2 transcription factors increased
transgene expression in BAC transgenic cell lines
BDNF is regulated by 9 different promoters containing
binding sites for different transcription factors regulating
expression of different BDNF transcripts. Of these tran-
scription factors CREB and bHLH transcription factor
heterodimer NPAS4-ARNT2 have been shown to regu-
late BDNF expression from various promoters [18,21,22].
To test if the transgenic cell lines could be used for
screening of transcription factors that induce BDNF tran-
scription we transfected cell lines 1A4s2 and 3E2s with
constructs expressing VP16-CREB (constitutively active
form of CREB1, fused with viral transactivation domain)
[62] or NPAS4 and ARNT2, or with empty pRC vector for
comparison.
24 hours after transfection VP16-CREB transcription
factor increased transgene expression in 1A4s2 and 3E2s
cell lines 1.55 (p < 0.01) fold. Transcription factor NPAS4
together with ARNT2 increased reporter expression in
1A4s2 and 3E2s cell lines 1.89 (p < 0.01) and 1.35 fold, re-
spectively (Figure 7A and B). These results show that
VP16-CREB and NPAS4-ARNT2 heterodimer increase
transgene expression in 1A4s2 and 3E2s rBDNF-hRluc-
EGFP cell lines.
Discussion
In the current study, we have developed rBDNF-hRluc-
EGFP reporter cell lines in HeLa background, using bac-
terial artificial chromosome (BAC) containing rat BDNF
genomic locus with protein coding region replaced with
hRluc-EGFP fusion reporter gene, for studying the regu-
lation of the BDNF gene and for analysis of the effect of
different compounds and transcription factors on BDNF
expression. Generation of transgenic mice for studying
BDNF regulation using large transgenic constructs by us
[50,51] and others [63] has shown that use of BAC (or
YAC) transgenic constructs helps to better recapitulate
endogenous BDNF expression. It has also been demon-
strated that using BAC constructs for generating cell
lines helps to avoid transgene integration specific effects
and provides levels and timing of transgene expression
that mimic that of the endogenous gene [64]. The large
rat BDNF genomic locus contained in the BAC construct
used in this work should include regulatory elements po-
sitioned further away from BDNF gene and help to bet-
ter emulate endogenous BDNF expression.
Out results show that rBDNF-hRluc-EGFP reporter
construct was maintained extrachromosomally in high
copy numbers in all established cell lines. Previously it
Figure 6 Treatment with HDAC inhibitors induces reporter expression in 1A4s2 and 3E2s rBDNF-hRluc-EGFP cell lines. (A, B, C, D) Fold
luciferase activity in HDAC inhibitor treated cells relative to vehicle treated cells (dashed line) measured in live cells during 12 hours. 1A4s2 and
3E2s cells were treated with HDAC inhibitors apicidin (100 nM) (A), SAHA (1 μM) (B), TSA (100 nM) (C), sodium valproate (1 mM) (D) and vehicle
control (0.1% DMSO or water) together with Enduren live cell substrate. Error bars indicate SD of three independent experiments (* p < 0.01, # p < 0.05,
relative to vehicle treated control). (E, F) Cell viability in HDAC inhibitor treated cells relative to vehicle treated cells after 12 hours of treatment in 1A4s2 cell
line (E) and 3E2s cell line (F). Viability was assayed by cellular ATP levels. Error bars indicate SD of three independent experiments.
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ment regions (MARs) are maintained in double minute
extrachromosomal elements in HeLa cells [65]. These
are autonomously replicating extrachromosomal ele-
ments that are up to a few Mb in size [66], have been
known to be associated with active histones [67] and can
be purified by histone immunoprecipitation [68]. MARs
and scaffold attachment regions (SARs), together named
as S/MARs, are regions on the DNA which attach to nu-
clear matrix and have been associated with functions
such as anchoring of DNA, maintenance of nuclear
architecture, regulation of transcription and replication.
It has been estimated that S/MARs are spaced on aver-
age 70 kb from each other in mammalian genomes [69].
Given the large size of BDNF locus contained in BAC
construct used in this study (207 kb) it is probable that
it contains S/MAR elements enabling extrachromosomal
maintenance in HeLa cells. We used SMARTest tool [70]
to predict the existence of 6 candidate sites in the genomic
locus included in rBDNF-hRluc-EGFP BAC which exhibitS/MAR like characteristics (data not shown). It would be
of interest to study which regions of the BDNF BAC used
in this study are responsible for its extrachromosomal
maintenance.
We detected expression of almost all 5′ exon-specific
BDNF mRNAs in the rBDNF-hRluc-EGFP cell lines show-
ing that the entire BDNF gene is maintained in inserted
transgene. We also observed stable and copy number
dependent expression of hRluc-EGFP fusion reporter pro-
tein by fluorescence and luminescence based methods. Pre-
viously it has been shown that protein expression in BAC
transgenic cell lines is proportional to transgene copy num-
bers [71]. BAC-derived BDNF gene is not highly expressed,
as shown by transgenic animals previously produced in our
lab where one or two copies of transgenic BDNF BAC con-
struct were inserted in the genome. In contrast, the high
copy numbers of transgene in the cell lines developed in
this study directed high levels of reporter gene expression.
We used hRluc-EGFP fusion protein, analogous to the
Rluc-GFP reporter used previously by [72], as a reporter
Figure 7 Overexpression of VP16-CREB and NPAS4+ARNT2 induces
reporter expression in 1A4s2 and 3E2s rBDNF-hRluc-EGFP cell lines.
(A, B) 1A4s2 (A) and 3E2s (B) cells were transfected with constructs
expressing VP16-CREB, NPAS4 and ARNT2 (at 1:1 ratio) transcription factors
or empty vector control pRC. Renilla luciferase luminescence was assayed
24 hours after transfection and fold luciferase activity relative to
empty vector control (pRC) was calculated. Error bars indicate SD.
(n – number of independent experiments, * p < 0.01, relative to
empty vector control).
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makes it possible to apply both fluorescence and more
sensitive luminescence based methods for reporter de-
tection. While EGFP fluorescence could be used for
measuring reporter expression via flow cytometry, use of
live cell substrates allow for sensitive detection of Renilla
luciferase signal which could be advantageous for high-
throughput screening procedures. The half-life of Renilla
luciferase is 3–4 hours and the half-life of EGFP is about
26 hours [73] in mammalian cells. However, stability of
the hRluc-EGFP fusion protein is not known. It is prob-
able that the induction of measurable reporter activity in
response to different treatments underestimates the true
effect on transcriptional activity due to slow turnover of
the hRluc-EGFP fusion protein, suggesting that it would
be important to develop a less stable hRluc-EGFP fusion
protein in future studies.
To assess the suitability of the cell lines generated by
us for use in studying BDNF gene regulation, the cells
were treated with stimuli known to induce BDNF ex-
pression. Ionomycin induces BDNF expression through
Ca2+ mediated signalling pathways [54], HDAC inhibi-
tors through increasing histone acetylation leading to tran-
scriptionally active chromatin around subset of genes,
including BDNF [56,74]. Transcription factor CREB and
NPAS4-ARNT2 heterodimer have been shown to promotetranscription from several BDNF promoters [18,21,22]. As
expected, treatment with different modulators of BDNF ex-
pression induced expression of hRluc-EGFP fusion re-
porter protein. The effect of treatment with ionomycin or
HDAC inhibitors was different when comparing high and
low transgene copy number cell lines. Ionomycin induced
reporter expression to a higher extent in lower copy num-
ber cell lines than in higher copy number cell lines. How-
ever, treatment of high and low transgene copy number
cell lines with different HDAC inhibitors induced trans-
gene expression similarly in both cell lines regardless of the
used inhibitor. The apparent copy number dependent ef-
fect on reporter induction by ionomycin might be ex-
plained by higher number of transcription factor response
elements in high copy number cell lines competing for lim-
ited supply of Ca2+ dependent transcription factors. In con-
trast, the effect of HDAC inhibitors on gene expression is
more general, regulating expression of large number of
genes, and they may act by inducing transgene expression
independent of copy number.
Since BDNF has been primarily studied as a neuronal
gene, the non-neuronal nature of the generated trans-
genic cell lines sets certain limitations to their use in
studying neuron-specific regulation of BDNF expression.
For example, BDNF mRNAs have been known to be
transported to dendrites [75,76] and their translation
there to be regulated in response to local synaptic signal-
ling [77], regulatory steps that are not recapitulated in
our cell lines. Also, neuronal stimuli known to regulate
BDNF expression, for example depolarisation by potas-
sium [54] or glutamate [78], do not recapitulate in HeLa
background. Therefore, modulators that have been found
to regulate transgene expression in these transgenic cell
lines should be also verified in neuronal background.
However, the active transcription of endogenous BDNF
mRNAs in HeLa cells and the robust nature of the HeLa
cells make these cell lines convenient tools for screening
of factors regulating BDNF expression.
Conclusions
In conclusion, we have generated a rBDNF-hRluc-EGFP
BAC cellular reporter model for use in studying BDNF
regulation. Transgene is maintained in cell lines extra-
chromosomally as high copy number episome. High
transgene copy number makes it possible to reliably de-
tect reporter expression. Transgene expression is induced
in response to known modulators of BDNF expression




BAC clone CH230-106 M15 containing rat BDNF gene
was purchased from Chori BACPAC Resources. Clone
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ning the BDNF gene locus cloned into the EcoRI site of
pTARBAC2.1 vector. The vector carried chloramphenicol
resistance and resided in E. coli host strain DH10B (recA−,
recBC+). Sequence of the BAC clone CH230-106 M15 was
obtained from NCBI GeneBank [GenBank:AC108236]. Vec-
tors pCDNA3.1-NPAS4, pCDNA3.1-ARNT2 and pACT-
CREB1 (containing VP16 viral transcription activation
domain) have been described previously [18].
Homologous recombination
BAC modifications using Red/ET homologous recom-
bination were performed according to the BAC Modifi-
cation Counter-Selection System protocol (Gene Bridges
GmbH). For amplification of inserts, 75-mer oligonucle-
otides were synthesised (Proligo). The 5′-end of each
oligonucleotide contained 50 nucleotides of homology
region shared by the target BAC and a linear insert
followed by a 25 nucleotide primer for PCR amplifica-
tion of the linear insert from the template. Where neces-
sary, linker sequence was added between homology arm
and primer sequences. Inserts for homologous recom-
bination were amplified by PCR using Expand Long
Template PCR system (Roche) or Hot GyroPol PCR sys-
tem (Solis BioDyne). The synthetic humanised version of
Renilla luciferase reporter gene (hRluc), the red-shifted
variant of wild-type Aequorea green fluorescent protein
(EGFP) reporter gene and SV40-Neor-polyA cassette
were amplified from pTK-hRluc (Promega), pEGFP-N1
(Clontech) and pEGFP-C1 vectors (Clontech), respect-
ively. Following PCR primers were used for insert syn-
thesis – hRLuc: sense 5′-CCT GTT CTG TGT CTG
TCT CTG CTC CTT CCC ACA GTT CCA CCA GGT
GAG AAG AGT GAT GGC TTC CAA GGT GTA
CGA CCC CG-3′, antisense 5′-ATA CAA ATA GAT
AAT TTT TGT CTC AAT ATA ATC TAT ACA ACA
TAA ATC CAT TAC TGC TCG TTC TTC AGC ACG
CGC T-3′; EGFP: sense 5′-TGG GTA AGT ACA TCA
AGA GCT TCG TGG AGC GCG TGC TGA AGA
ACG AGC AGG CCG CCG CCG CCA CCA TGG TGA
GCA AGG GCG AGG AGC TG-3′, antisense 5′-ATA
CAA ATA GAT AAT TTT TGT CTC AAT ATA ATC
TAT ACA ACA TAA ATC CAT TAC TTG TAC AGC
TCG TCC ATG CCG A-3′; SV40- Neor -polyA cassette:
sense 5′-CAC CAT AAT GAA ATA AGA TCA CTA
CCG GGC GTA TTT TTT GAG TTA TCG AGA TTT
TCA GGA GCT AAG GAA GCT AAA TTC AAA TAT
GTA TCC GCT CAT GAG A-3′, antisense 5′-ATT CAT
CCG CTT ATT ATC ACT TAT TCA GGC GTA GCA
ACC AGG CGT TTA AGG GCA CCA ATA ACT GCC
TTT TTT ATT CTG TCT TTT TAT TGC CGT C-3′.
BAC was modified by first replacing BDNF protein coding
region with hRluc coding sequence, then inserting Ala-
Ala-Ala-Thr linker and EGFP coding sequences to the endof hRluc sequence and finally by replacing the CAT gene
in BAC vector with SV40-Neor-polyA cassette. The modi-
fied BAC containing colonies were screened by colony
PCR and colony hybridisation and further verified by re-
striction analysis and sequencing.
Cell culture and transfection
HeLa (DSMZ) human cervical cancer cells were propa-
gated in DMEM (Dulbecco’s Modified Eagle Medium;
PAA) supplemented with 10% fetal bovine serum (PAA),
penicillin (PAA) and streptomycin (PAA) at 37°C in 5%
CO2. For BAC DNA transfection 1 μg of BAC DNA
purified with Large-Construct Kit (Qiagen) was mixed
with 5 × 106 HeLa cells and transfection was performed
using Amaxa Nucleofector program A-28 and Cell Line
Nucleofector Kit R (Amaxa). 72 hours later 400 μg/
ml G418 (Sigma) was added to the growth medium to
select for BAC containing cells. After two months of se-
lection, single EGFP-positive clones were isolated with
FACSAria cell sorting system (Becton-Dickinson). The
cell lines were routinely grown in medium containing
800 μg/ml G418. For transfection of plasmid constructs
cells were seeded into white 96-well clear bottom micro-
titer plate (Greiner Bio-One) at 10 000 cells per well in a
volume of 200 μl of G418-containing culture medium.
The next day medium was replaced with 100 μl of
medium without G418 and cells were transfected with
GenJet Hela transfection reagent (SignaGen Laborator-
ies) using 100 ng of DNA per well at 1:3 DNA to lipid
ratio. NPAS4 and ARNT2 constructs were cotransfected
at 1:1 ratio. Five hours post-transfection medium was re-
placed with 200 μl of G418-containing medium.
Drug treatments
One day before treatments, cells were seeded into white
96-well clear bottom microtiter plates (Greiner Bio-One)
at 10 000 cells per well. The next day medium was re-
placed with 75 μl of fresh medium containing ionomy-
cin, apicidin, sodium valproate (all Sigma Aldrich), SAHA
or TSA (both Cayman Chemical). All drugs except sodium
valproate were dissolved in DMSO and added to cells at a
final DMSO concentration of 0.1%. Sodium valproate was
dissolved in MilliQ grade water. Appropriate vehicle con-
trols (DMSO or water) were included in all experiments.
Reporter assays
EGFP was detected by fluorescence microscopy (Axiovert
200 M, Zeiss) and flow cytometry (FACSCalibur, Becton-
Dickinson). In flow-cytometric analysis no compensation
was used and markers for positive EGFP-signals were set
on FL1 vs FL2 dot blot using the autofluorescence diag-
onal of parental HeLa cells. EGFP-positive cells were iden-
tified by divergence from the autofluorescence diagonal
towards higher FL1 fluorescence. For monitoring hRluc
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(Promega) was added to cells at the beginning of drug
treatment and luminescence was measured once per hour
at 2–12 hour time points. For measuring endpoint hRluc
activity, cells were lysed in 20 μl Passive Lysis Buffer (Pro-
mega) 24 hours after transfection and subjected to
Renilla-Glo Luciferase Assay System (Promega) according
to the manufacturer’s instructions. Relative luminescence
was measured with GENios Pro plate reader (TECAN).
For normalisation and monitoring cell viability ViaLight
Plus Cell Proliferation And Cytotoxicity BioAssay Kit
(Lonza, USA) were used. For drug treatments, three inde-
pendent experiments were performed, each in triplicate.
Luciferase signal in response to drug treatments was nor-
malised to vehicle control for each time point, means and
standard deviations were calculated and t-tests for analysis
of statistical significance for indicated time points were
performed. For transcription factor transfections, four or
five independent experiments were performed, each in
triplicate. Luciferase signal in response to expression of
transcription factor(s) was normalised to signal in pRC
empty vector transfected cells, means and standard devia-
tions were calculated and t-tests for analysis of statistical
significance were performed.
Fluorescence in situ hybridisation
Mitotic blocking was performed by treating cells with
50 ng/ml colcemid (Sigma) for 4 hours. The cells were
harvested by shakeoff and subjected to hypotonic treat-
ment with 0.075 M KCl for 15 min. The cells were fixed
in methanol:acetic acid (3:1) and used for chromosome
slide preparation. Slides were chemically aged and dena-
tured as described [79]. Prior to denaturation and hy-
bridisation, chromosome preparations were treated with
RNase A (100 μg/ml in 2 × SSC), pepsin (50 μg/ml in
0.01 N HCl) and 1% formaldehyde (in PBS containing
50 mM MgCl2). rBDNF-hRluc-EGFP BAC specific probe
was labeled with digoxigenin-11-dUTP (Roche) by nick
translation. For each hybridisation 45 ng of the labeled
probe was used together with 25 μg of salmon sperm
DNA. Hybridisation was carried out by incubating slides
in 50% deionised formamide, 2 × SSC, 0.1 M phosphate
buffer, 10% dextran sulfate overnight at 37°C in humid
chamber. Hybridised probe was detected by affinity reaction
with mouse anti-digoxygenin primary antibody (Roche)
followed by Alexa 546 conjugated anti-mouse secondary
antibody (Life Technologies, USA) and chromosomes were
counterstained with Hoecht 33342. Slides were mounted
in ProLong Gold anti-fade reagent (Life Technologies,
USA) and imaged with Zeiss LSM DUO microscope.
RNA extraction and RT-PCR
Total RNA from cells was purified with RNeasy Micro
kit (Quiagen) as recommended by the manufacturer andtreated with DNase I using DNA-free kit (Ambion).
First-strand cDNA was synthesised from 5 μg of total
RNA with Superscript III reverse transcriptase (Life Sci-
ences) according to manufacturer’s recommendations.
PCR reactions were performed with HotFire polymerase
(Solis Biodyne) in a volume of 10 μl containing 1/80 of
reverse transcription reaction as a template. Human
BDNF 5′ exons’ specific primers have been described
previously [12]. Rat BDNF 5′ exons’ specific primers
have been described previously [11] and were used in
combination with hRluc specific antisense primer 5′-GTA
CTT GTA GTG ATC CAG GAG GCG AT-3′.
Genomic DNA extraction and quantitative PCR
Genomic DNA was extracted from cells by proteinase K
digestion and phenol:chloroform extraction followed by
ethanol precipitation and resuspension overnight in TE
(pH 8.0). Genomic DNA concentration was quantified
with UV spectrophotometer (NanoDrop) and diluted to
16 ng/μl for qPCR. For standard curve, a series of mix-
tures in which the number of pEGFP-C1 (Promega)
plasmid molecules ranged from 128 to 1024 copies per
HeLa genome were prepared using HeLa genomic DNA.
32 ng of genomic DNA from different cell lines or copy
number standards were subjected to quantitative PCR.
Quantitative PCR was performed on Roche LightCycler
2.0 using qPCR Core kit for SYBR® Green I No ROX
(Eurogentec). qPCR reactions with copy number stan-
dards were performed in duplicate. qPCR reactions with
cell line genomic DNAs were performed in triplicate.
Melting curve analysis was carried out at the end of cyc-
ling to confirm amplification of a single PCR product.
Following EGFP and human TRKB (genomic control)
specific PCR primer sets were used: EGFP sense 5′- CAG
AAG AAC GGC ATC AAG GTG-3′, antisense 5′- TGG
GTG CTC AGG TAG TGG TTG -3′; TRKB sense
5′- CAC AGG GCT CCT TAA GGA TAA C -3′, anti-
sense 5′- GCA CAG TGA GGT TGA CAG AAT C-3′.
Copy number estimates were calculated with qBASEPlus
2.6 software (Biogazelle) using EGFP as target and TRKB
as reference.
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